Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems

Blood

Volumn 120, Issue 17, 2012, Pages 3444-3454

  Yokota, Yosuke ^a   Inoue, Hiroyuki ^a,b,c   Matsumura, Yumiko ^a   Nabeta, Haruka ^a   Narusawa, Megumi ^a   Watanabe, Ayumi ^a   Sakamoto, Chika ^a   Hijikata, Yasuki ^c   Iga Murahashi, Mutsunori ^c   Takayama, Koichi ^b   Sasaki, Fumiyuki ^b   Nakanishi, Yoichi ^b   Yokomizo, Takehiko ^b   Tani, Kenzaburo ^a,c  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; FLOW CYTOMETRY; GENE TARGETING; GENETIC TRANSDUCTION; IMMUNE SYSTEM; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; KNOCKOUT MOUSE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

EID: 84868562993     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-383240     Document Type: Article

References (50)

1. Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 2009;100(8):1389-1396.
2. Tani K, Azuma M, Nakazaki Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther. 2004;10(4):799-816. (Pubitemid 39272869)
3. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002;188:147-154. (Pubitemid 35398872)
4. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90(8):3539-3543. (Pubitemid 23111402)
5. Inoue H, Iga M, Nabeta H, et al. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Sci. 2008;99(11):2315- 2326.
6. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21(4):624- 630.
7. Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009;106(37):15825-15830.
8. Nakazaki Y, Hase H, Inoue H, et al. Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses. Mol Ther. 2006;14(4):599-606. (Pubitemid 44296094)
9. Simmons AD, Li B, Gonzalez-Edick M, et al. GM-CSF- secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother. 2007;56(10):1653-1665. (Pubitemid 47094396)
10. Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther. 2005;12(1):18-27. (Pubitemid 40862352)
11. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323(10):645-655. (Pubitemid 20280195)
12. Naccache PH, Sha'afi RI. Arachidonic acid, leukotriene B4, and neutrophil activation. Ann N Y Acad Sci. 1983;414:125-139. (Pubitemid 14180791)
13. Del Prete A, Shao WH, Mitola S, Santoro G, Sozzani S, Haribabu B. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood. 2007;109(2):626-631. (Pubitemid 46105963)
14. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. AG-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997;387(6633):620-624. (Pubitemid 27248768)
15. Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y. The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990;Suppl 1:35-44.
16. Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP. Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol. 2002;169(6):2875-2885. (Pubitemid 35013128)
17. Terawaki K, Yokomizo T, Nagase T, et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol. 2005; 175(7):4217-4225. (Pubitemid 41361955)
18. Nakazaki Y, Tani K, Lin ZT, et al. Vaccine effect of granulocyte- macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity. Gene Ther. 1998;5(10):1355-1362. (Pubitemid 28482663)
19. Kruisbeek AM. In vivo depletion of CD4- and CD8-specific T cells. Curr Protoc Immunol. 1991;Chapter 4:Unit 4 1.
20. Inoue H, Iga M, Xin M, et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother. 2008;57(9):1399-1411.
21. Nurieva R, Yang XO, Chung Y, Dong C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J Immunol. 2009;182(5):2565-2568.
22. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res. 2004;64(3):1037-1043. (Pubitemid 38176907)
23. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97(2):339-345. (Pubitemid 32060315)
24. Tong WG, Ding XZ, Hennig R, et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2002;8(10):3232-3242. (Pubitemid 35155036)
25. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci. 2007;103(1):24-32. (Pubitemid 46175592)
26. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 2000;60(12):3239-3246. (Pubitemid 30407923)
27. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64(17):6337-6343. (Pubitemid 39129439)
28. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188(12):2357-2368. (Pubitemid 29028508)
29. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3(2):135-142. (Pubitemid 34141443)
30. Nocentini G, Riccardi C. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol. 2005;35(4):1016-1022. (Pubitemid 40542207)
31. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol. 2000;1(1):47-53.
32. Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005;26(4):785-791. (Pubitemid 41214341)
33. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996;97(3):806-813. (Pubitemid 26057100)
34. Yokomizo T. Leukotriene B4 receptors: novel roles in immunological regulations. Adv Enzyme Regul. 2011;51(1):59-64.
35. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1):15-22. (Pubitemid 39626587)
36. Toda A, Terawaki K, Yamazaki S, Saeki K, Shimizu T, Yokomizo T. Attenuated Th1 induction by dendritic cells from mice deficient in the leukotriene B4 receptor 1. Biochimie. 2010;92(6):682-691.
37. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251-262. (Pubitemid 37323225)
38. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science. 2001;293(5528):248- 250. (Pubitemid 32694731)
39. Kitajima M, Ito T, Tumes DJ, et al. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells. Cancer Res. 2011;71(14):4790-4798.
40. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141-1149.
41. Muranski P, Restifo NP. Does IL-17 promote tumor growth? Blood. 2009;114(2):231-232.
42. Bronte V. Th17 and cancer: friends or foes? Blood. 2008;112(2):214.
43. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247-258. (Pubitemid 351432801)
44. Gualde N, Cogny van Weydevelt F, Buffiere F, Jauberteau MO, Daculsi R, Vaillier D. Influence of LTB4 on CD4-, CD8- thymocytes: evidence that LTB4 plus IL-2 generate CD8+ suppressor thymocytes involved in tolerance to self. Effect of LTB4 and IL-2 on double negative thymocytes. Thymus. 1991;18(2):111-128.
45. Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005;22(3):371-383. (Pubitemid 40387478)
46. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;12(6):677-686.
47. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. Asecond leukotriene B(4) receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000;192(3):421-432.
48. Okuno T, Iizuka Y, Okazaki H, Yokomizo T, Taguchi R, Shimizu T. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med. 2008;205(4):759-766. (Pubitemid 351549875)
49. Lin PY, Sun L, Thibodeaux SR, et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol. 2010;185(5):2747-2753.
50. Scotland RS, Stables MJ, Madalli S, Watson P, Gilroy DW. Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. Blood. 2011;118(22):5918-5927.